Rate My Professor Yasir Khan

Dr Yasir Khan serves as Adjunct Clinical Senior Lecturer in the Curtin Medical School within the Faculty of Health Sciences at Curtin University, where he contributes to medical education by mentoring medical students and junior doctors. He earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) from the University of Health Sciences Lahore in 2008 and holds Fellowship of the Royal Australasian College of Physicians (FRACP). Khan completed specialist oncology training at Sir Charles Gairdner Hospital and Fiona Stanley Hospital in Western Australia. In 2020, he was the lead clinical research fellow during a one-year fellowship in melanoma and kidney cancers at The Royal Marsden Hospital in London, participating in novel cell therapy clinical trials and multiple research projects. His career includes roles at Royal Perth Hospital from February to September 2021, and currently, he is Head of the Oncology Department at Peel Health Campus since September 2021, Head of Medical Specialities since August 2024, and practices at St John of God Midland Hospital and Icon Cancer Centre Midland.

Khan specializes in medical oncology with clinical interests spanning breast cancer, genitourinary cancers, gastrointestinal cancers, lung cancer, melanoma, head and neck cancer, gynaecological cancer, colorectal cancer, pancreatic cancer, gallbladder cancer, and non-melanoma skin cancer. A strong advocate for clinical trials and local research, he serves as sub-investigator on trials involving autologous tumour-infiltrating lymphocyte and CAR-T cell therapies. His research interests include genitourinary cancers, lung cancers, melanoma, immunotherapy-based treatments, and novel immunotherapy agents. With 23 publications and 245 citations on Google Scholar and ResearchGate, notable works include 'Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study' in Nature Cancer (2021), 'Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma' in Cancers (2020), 'Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma' in Journal of Clinical Oncology (2022), 'Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study' in European Journal of Cancer (2022), and 'Stromal inflammation, fibrosis and cancer: An old intuition with promising potential' in World Journal of Clinical Oncology (2023). Khan is involved in professional groups such as ANZUP, WACPCN Thoracic Tumour Collaborative, and ANZGOG.